ArticleBMC health services research2021
The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran.
Article in BMC health services research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.PharmacoEconomics - open · 2026Pooled it
- The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- The expected economic burden on the healthcare system because of quarantining patients with monkeypox virus.Saudi medical journal · 2023Pooled it
- Main social vulnerability indicators in the COVID-19 pandemic in Iran.Frontiers in public health · 2023Pooled it
- Costs of inpatient care and out-of-pocket payments for COVID-19 patients: A systematic review.PloS one · 2023Pooled it
- Hospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic review.PloS one · 2022Pooled it
- Economic costs related to coronavirus disease 2019 pandemic: A systematic literature review.Science progressPooled it
- Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial.Advances in respiratory medicine · 2023Trial
- Cost-effectiveness of plasmapheresis and hemoperfusion in COVID-19 survivors: A six-month follow-up analysis after hospital discharge.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Article
- The economic impact of COVID-19: a comparative cost analysis of ICU hospitalizations before and during the pandemic.Clinics (Sao Paulo, Brazil) · 2026Article
- Article
- Article
- The economic burden of COVID-19 premature mortality in Kuwait.BMC public health · 2025Article
- Efficiency in COVID-19 inpatient care: findings from public hospitals in Iran.Health economics review · 2025Article
- Estimating the direct medical cost of illness of COVID-19 hospitalisations in Kuwait: efficiency trade-offs from real-world data analysis.Health economics review · 2025Article
- Lessons from the pandemic: an interrupted time series analysis of food and non-food household expenditures in Iran.BMC public health · 2025Article
- Adjusting hospital reimbursements to the onset of a new disease: Lesson from Covid-19.Health policy OPEN · 2025Article
- Assessment of COVID-19 hospitalisation cost and its associated factors in Nepal: a descriptive cross-sectional study.BMJ open · 2025Article
- The impact of COVID-19: consequences of a 3-Year struggle in Iran.BMC infectious diseases · 2025Article
- Direct medical cost of adult Covid-19 ınpatients and ıts determinants at a university hospital.PloS one · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to estimate both direct medical and indirect costs of treating the Coronavirus disease 2019 (COVID-19) from a societal perspective in the patients at a referral hospital in Fars province as well as the economic burden of COVID-19 in Iran in 2020.
methodsThis study is a partial economic evaluation and a cross-sectional cost-description study conducted based on the data of the COVID-19 patients referred to a referral university hospital in Fars province between March and July 2020. The data were collected by examining the patients' records and accounting information systems. The subjects included all the inpatients with COVID-19 (477 individuals) who admitted to the medical centre during the 4 months. Bottom-up costing (also called micro-costing approach), incidence-based and income-based human capital approaches were used as the main methodological features of this study.
resultsThe direct medical costs were estimated to be 28,240,025,968 Rials ($ 1,791,172) in total with mean cost of 59,203,409 Rials ($ 3755) per person (SD = 4684 $/ 73,855,161 Rials) in which significant part (41%) was that of intensive and general care beds (11,596,217,487 Rials equal to $ 735,510 (M = 24,310,728 Rials or $ 1542, SD = 34,184,949 Rials or $ 2168(. The second to which were the costs of medicines and medical consumables (28%). The mean indirect costs, including income loss due to premature death, economic production loss due to hospitalization and job absenteeism during recovery course were estimated to be 129,870,974 Rials ($ 11,634) per person. Furthermore, the economic burden of the disease in the country for inpatient cases with the definitive diagnosis was 22,688,925,933,095 Rials equal to $ 1,439,083,784.
conclusionThe results of this study showed that the severe status of the disease would bring about the extremely high cost of illness in this case. It is estimated that the high prevalence rate of COVID-19 has been imposing a heavy economic burden on the country and health system directly that may result in rationing or painful cost-control approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.